Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SimpPrEP: Event-driven PrEP for HIV Using TAF/FTC in MSM
NCT05813964Phase 3Recruiting
- Sponsor
- ANRS
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoint: Efficacy of F/TAF in reducing the risk of HIV acquisition. Started Jun 2024; status: recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05813964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813964.